Corning Life Science Bio-Expo Live June 2026: Upstream Bioprocessing

Scaling adherent cell cultures for vaccine manufacturing is not simply a matter of increasing surface area. As processes move beyond T-flasks, manufacturers must decide between scaling out with static multi-layer vessels or intensifying production with automated perfusion-based systems. Static platforms can closely mirror familiar flask-based behavior, but higher viral production often introduces metabolic constraints such as rapid glucose consumption and lactate buildup. Perfusion-enabled bioreactors offer a different path by maintaining tighter control over pH, dissolved oxygen, and nutrient availability, helping extend culture productivity and reduce process stress. The strongest platform choice depends on how a given cell line behaves under scale and what level of throughput the process must support.

Uncover the tradeoffs shaping adherent scale-up strategies and what they mean for robust, efficient vaccine production.